We previously reported that patients with ALL or AML transplanted with unrelated umbilical cord blood (CB) grafts had a substantially higher rate of leukemic relapse if the patient did not share any of the HLA Ags identified as CB donor inherited paternal Ags (IPAs), and/or there were no target Ags in the CB donor that could induce maternal anti-IPA HLA immunity. 1 These data are suggestive of a pivotal role of chimeric maternal T cells present in the CB, and reactive with the inherited paternal HLA Ags of the cord blood donor. Of note, we also reported that relapse risk was significantly lower when the CB came from a second or subsequently born child than from firstborn children. To further explore relapse risk, we examine herein the potential additional impact of birth order and gender in patients who shared one or more Ag with the donor's IPAs and those who did not.
We performed this analysis on the same cohort as previously published. 1 The 799 evaluable patients were those with either ALL or AML who were given a single cord blood unit (CBU) from the New York Blood Centre (NYBC), National Cord Blood Program between 1993 and 2006. We included only those with 1-3 HLA mismatches between CBU donor and the recipient (HLA-A or B at intermediate resolution; DRB1 at high resolution). One patient whose donor's sex was unknown was excluded. All HLA-matched patients (n = 45) had a shared IPA and were excluded for analysis.
When patients had Ags that were matched with one or more of the donor's IPAs they were classified as having a 'shared IPA' (n = 750). The remaining 49 patients did not share HLA Ags with their respective CB IPAs (n = 33) or the CB had no IPA target for maternal cells (n = 16, six of which were identifiable without maternal HLA typing because all three CBU loci were homozygous).
Patients with shared IPA and no shared IPA did not differ from each other except for number and direction of HLA mismatches (as per Supplemental Table S1 , van Rood JJ et al. ). Multivariate analyses for relapse risk included HLA mismatch and direction, International Bone Marrow Registry (IBMTR) relapse risk, diagnosis, GvHD prophylaxis, birth order and non inherited maternal antigens (NIMA) match.
The primary study end point was post-transplant relapse. The cumulative incidence of relapse in the first 3 years post transplantation among study patients was 23.0%, the vast majority (82%) occurring in the first year. Among patients having one or more shared IPA with the graft, the relapse rate was 21.4% compared to 48.6% in the no shared IPA group (hazard ratio (HR) = 0.36, 95% confidence interval (CI) = 0.33-0.58, P o0.001).
When both donor gender as well as birth order were considered, no significant differences in relapse rates were found in the shared IPA group (Figure 1a) . In contrast, in the no shared IPA group (Figure 1b) patients given CBUs from a firstborn female donor had the highest cumulative incidence of relapse of 78%. Patients given CBUs from female donors from second or subsequent pregnancies ('second born') or firstborn male donors had slightly lower relapse rates but the differences were not significant. When the donor was male and second born, the relapse rate was significantly lower than that of firstborn female donors (univariate HR = 0.1, 95% CI = 0.0-0.4, P = 0.002) and similar to that of the shared IPA group (Figure 1b) . A causative factor explaining the difference between female and male second grafts has not been identified, but might be due to more effective regulatory mechanisms in the female CBU.
While our current findings are intriguing, we recognize that they are based on one study only. Moreover, taking donor gender and birth order into account in CB unit selection when there is no IPA match might avoid a high risk of relapse in some patients (65% of the 49 patients with no IPA match in our study). Nevertheless, we felt an obligation to report our findings to encourage others to explore these issues in independent study populations, and to remember that in selecting a CBU for a hematopoietic stem cell transplantation the number of nucleated cells and the HLA match are not the only factors which are of importance. In the context of our findings, it is fortunate that more and more Cord Blood Banks record the HLA phenotype of the mother, made possible thanks to the price reduction of HLA typing by new generation sequence typing.
